Oronzo Brunetti

Closest collaborators

The 25 strongest of 79 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Nicola Silvestris · 18 shared papers, 2015–2026 · strength 1.79
   • Paper Is it Time for a Therapeutic Algorithm in Resected Pancreatic Ductal Adenocarcinoma? DOI 10.1097/mpa.0000000000001449↗
   • Paper Integrated single cell RNA sequencing and flow cytometry analysis identifies elevated S100A6+ and S100A8+ myeloid subse… DOI 10.1016/j.clim.2026.110665↗
   • Paper Evolving pancreatic cancer treatment: From diagnosis to healthcare management. DOI 10.1016/j.critrevonc.2021.103571↗
2. Antonella Argentiero · 6 shared papers, 2018–2020 · strength 0.62
   • Paper Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a… DOI 10.1155/2020/8679751↗
   • Paper Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review. DOI 10.1002/ccr3.2412↗
   • Paper Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma: Could Surgery Represent a Ther… DOI 10.20944/preprints201908.0278.v1↗
3. Antonio Giovanni Solimando · 5 shared papers, 2019–2020 · strength 0.54
   • Paper Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma, When Surgery Could Represent a… DOI 10.1155/2020/8679751↗
   • Paper Bone metastasis as primary presentation of pancreatic ductal adenocarcinoma: A case report and literature review. DOI 10.1002/ccr3.2412↗
   • Paper Complete Response of Synchronous Liver Metastasis in a Pancreatic Ductal Adenocarcinoma: Could Surgery Represent a Ther… DOI 10.20944/preprints201908.0278.v1↗
4. Massimo Falconi · 5 shared papers, 2016–2023 · strength 0.52
   • Paper Immunonutrition and prehabilitation in pancreatic cancer surgery: A new concept in the era of ERAS® and neoadjuvant tre… DOI 10.1016/j.ejso.2022.12.006↗
   • Paper Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer. DOI 10.3390/cancers12020275↗
   • Paper Evolving pancreatic cancer treatment: From diagnosis to healthcare management. DOI 10.1016/j.critrevonc.2021.103571↗
5. Amalia Azzariti · 5 shared papers, 2015–2026 · strength 0.51
   • Paper Integrated single cell RNA sequencing and flow cytometry analysis identifies elevated S100A6+ and S100A8+ myeloid subse… DOI 10.1016/j.clim.2026.110665↗
   • Paper Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Sig… DOI 10.3390/cancers11070942↗
   • Paper CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic C… DOI 10.3390/cancers11030330↗
6. Michèle Milella · 4 shared papers, 2020–2023 · strength 0.48
   • Paper Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer. DOI 10.3390/cancers12020275↗
   • Paper Evolving pancreatic cancer treatment: From diagnosis to healthcare management. DOI 10.1016/j.critrevonc.2021.103571↗
   • Paper Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. DOI 10.1016/j.modpat.2023.100251↗
7. Letizia Porcelli · 4 shared papers, 2016–2026 · strength 0.47
   • Paper Integrated single cell RNA sequencing and flow cytometry analysis identifies elevated S100A6+ and S100A8+ myeloid subse… DOI 10.1016/j.clim.2026.110665↗
   • Paper Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Sig… DOI 10.3390/cancers11070942↗
   • Paper CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic C… DOI 10.3390/cancers11030330↗
8. Raffaele De Luca · 2 shared papers, 2023–2026 · strength 0.42
   • Paper Nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil for metastatic pancreatic ducta… DOI 10.1007/s10585-026-10401-5↗
   • Paper Immunonutrition and prehabilitation in pancreatic cancer surgery: A new concept in the era of ERAS® and neoadjuvant tre… DOI 10.1016/j.ejso.2022.12.006↗
9. Michele Reni · 5 shared papers, 2015–2022 · strength 0.37
   • Paper Evolving pancreatic cancer treatment: From diagnosis to healthcare management. DOI 10.1016/j.critrevonc.2021.103571↗
   • Paper Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evide… DOI 10.3390/cancers12061681↗
   • Paper Multimodal treatment of resectable pancreatic ductal adenocarcinoma. DOI 10.1016/j.critrevonc.2017.01.015↗
10. Aldo Scarpa · 5 shared papers, 2015–2023 · strength 0.33
    • Paper Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. DOI 10.1016/j.modpat.2023.100251↗
    • Paper Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ducta… DOI 10.2147/ott.s106496↗
    • Paper Multimodal treatment of resectable pancreatic ductal adenocarcinoma. DOI 10.1016/j.critrevonc.2017.01.015↗
11. Riccardo Memeo · 2 shared papers, 2019–2026 · strength 0.32
    • Paper Integrated single cell RNA sequencing and flow cytometry analysis identifies elevated S100A6+ and S100A8+ myeloid subse… DOI 10.1016/j.clim.2026.110665↗
    • Paper Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer. DOI 10.3390/cancers11111718↗
12. Riccardo Caccialanza · 2 shared papers, 2020–2023 · strength 0.28
    • Paper Immunonutrition and prehabilitation in pancreatic cancer surgery: A new concept in the era of ERAS® and neoadjuvant tre… DOI 10.1016/j.ejso.2022.12.006↗
    • Paper Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer. DOI 10.3390/cancers12020275↗
13. Enrico Vasile · 3 shared papers, 2017–2022 · strength 0.28
    • Paper Evolving pancreatic cancer treatment: From diagnosis to healthcare management. DOI 10.1016/j.critrevonc.2021.103571↗
    • Paper Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evide… DOI 10.3390/cancers12061681↗
    • Paper Multimodal treatment of resectable pancreatic ductal adenocarcinoma. DOI 10.1016/j.critrevonc.2017.01.015↗
14. Ugo Boggi · 2 shared papers, 2022–2023 · strength 0.28
    • Paper Immunonutrition and prehabilitation in pancreatic cancer surgery: A new concept in the era of ERAS® and neoadjuvant tre… DOI 10.1016/j.ejso.2022.12.006↗
    • Paper Evolving pancreatic cancer treatment: From diagnosis to healthcare management. DOI 10.1016/j.critrevonc.2021.103571↗
15. Salvatore Paiella · 2 shared papers, 2023 · strength 0.27
    • Paper Immunonutrition and prehabilitation in pancreatic cancer surgery: A new concept in the era of ERAS® and neoadjuvant tre… DOI 10.1016/j.ejso.2022.12.006↗
    • Paper Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. DOI 10.1016/j.modpat.2023.100251↗
16. Roberto Salvia · 2 shared papers, 2023 · strength 0.27
    • Paper Immunonutrition and prehabilitation in pancreatic cancer surgery: A new concept in the era of ERAS® and neoadjuvant tre… DOI 10.1016/j.ejso.2022.12.006↗
    • Paper Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. DOI 10.1016/j.modpat.2023.100251↗
17. Elsa Vitale · 1 shared paper, 2026 · strength 0.27
    • Paper Nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil for metastatic pancreatic ducta… DOI 10.1007/s10585-026-10401-5↗
18. Giuseppe Malleo · 2 shared papers, 2022–2023 · strength 0.25
    • Paper Evolving pancreatic cancer treatment: From diagnosis to healthcare management. DOI 10.1016/j.critrevonc.2021.103571↗
    • Paper Clinical and Genomic Characterization of Pancreatic Ductal Adenocarcinoma with Signet-Ring/Poorly Cohesive Cells. DOI 10.1016/j.modpat.2023.100251↗
19. Rosa Maria Iacobazzi · 3 shared papers, 2016–2019 · strength 0.24
    • Paper Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Sig… DOI 10.3390/cancers11070942↗
    • Paper CAFs and TGF-β Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic C… DOI 10.3390/cancers11030330↗
    • Paper Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ducta… DOI 10.2147/ott.s106496↗
20. Raffaele Pezzilli · 2 shared papers, 2020 · strength 0.23
    • Paper Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer. DOI 10.3390/cancers12020275↗
    • Paper Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Exocrine Pancreatic Ductal Adenocarcinoma: Evide… DOI 10.3390/cancers12061681↗
21. Afshin Derakhshani · 1 shared paper, 2026 · strength 0.23
    • Paper Integrated single cell RNA sequencing and flow cytometry analysis identifies elevated S100A6+ and S100A8+ myeloid subse… DOI 10.1016/j.clim.2026.110665↗
22. Vito Racanelli · 1 shared paper, 2026 · strength 0.23
    • Paper Integrated single cell RNA sequencing and flow cytometry analysis identifies elevated S100A6+ and S100A8+ myeloid subse… DOI 10.1016/j.clim.2026.110665↗
23. Mario Testini · 1 shared paper, 2026 · strength 0.23
    • Paper Integrated single cell RNA sequencing and flow cytometry analysis identifies elevated S100A6+ and S100A8+ myeloid subse… DOI 10.1016/j.clim.2026.110665↗
24. Adib Miraki Feriz · 1 shared paper, 2026 · strength 0.23
    • Paper Integrated single cell RNA sequencing and flow cytometry analysis identifies elevated S100A6+ and S100A8+ myeloid subse… DOI 10.1016/j.clim.2026.110665↗
25. Behzad Baradaran · 1 shared paper, 2026 · strength 0.23
    • Paper Integrated single cell RNA sequencing and flow cytometry analysis identifies elevated S100A6+ and S100A8+ myeloid subse… DOI 10.1016/j.clim.2026.110665↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.